Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - BioMarin Pharmaceutical (NasdaqNM:BMRN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
371 Bel Marin Keys Boulevard, Suite 210
Novato, CA 94949
Phone: (415) 884-6700
Fax: (415) 382-7427
Email: jprice@biomarinpharm.com
Employees (last reported count): 200
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 73%
·Over the last 6 months:
 · one insider buy; 423.0K shares (1.4% of insider shares)
 · 2 insider sells; 58.0K shares
  (0.2% of insider shares)
·Institutional: 13% (47% of float)
(77 institutions)
·Net Inst. Buying: 3.23M shares (+37.71%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
BioMarin Pharmaceutical Inc. develops enzyme therapies to treat debilitating, life-threatening genetic diseases and other indications. The Company has two enzyme replacement therapies in clinical trials and recently filed an application to enter a third enzyme into the clinic. Aldurazyme, a joint venture with Genzyme General, is an enzyme replacement therapy in a 45 patient, double-blind, placebo-controlled Phase III clinical trial to treat Mucopolysaccharidosis I (MPS I), a life-threatening genetic disease. On July 20, 2001, the Company completed the 24 week treatment stage of its Phase I clinical trial of rhASB, an enzyme replacement therapy for the treatment of MPS VI, a disease clinically similar to MPS I. Aldurazyme and rhASB have both received fast track status from the FDA, and they have also each been granted orphan designations in the U.S. and EU. The Company is also developing Vibriolysin Topical, an enzymatic gel for wound debridement (cleaning) in serious burn patients.
More from Market Guide: Expanded Business Description

Financial Summary
BioMarin Pharmaceutical Inc. develops enzyme therapies to treat debilitating, life-threatening genetic diseases and other indications. For the six months ended 6/30/01, revenues increased 11% to $7.1 million. Net loss rose 15% to $21.7 million. Revenues benefited from increased sales generated by Glyko, Inc. Net loss reflects increased research and development expenses and a higher equity in loss related to BioMarin/Genzyme LLC.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Fredric Price, 55
Chairman, CEO
$778K
Raymond Anderson, 59
CFO, Chief Operating Officer, VP of Fin. and Admin., Sec.
249K
Robert Baffi, Ph.D., 46
VP, Quality Assurance and Quality Control
--  
Brian Brandley, Ph.D., 44
VP of BioMarin and Managing Director, Glyko, Inc.
--  
John Jost, Ph.D., 56
VP, Manufacturing
252K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:BMRNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Mar-2001
$6.563
Recent Price$12.21 
52-Week High
on 29-Sep-2000
$19.125
Beta1.08 
Daily Volume (3-month avg)58.0K
Daily Volume (10-day avg)62.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-26.3%
52-Week Change
relative to S&P500
-1.1%
Share-Related Items
Market Capitalization$513.4M
Shares Outstanding42.0M
Float11.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.21 
Earnings (ttm)-$1.07 
Earnings (mrq)-$0.30 
Sales (ttm)$0.35 
Cash (mrq)$1.42 
Valuation Ratios
Price/Book (mrq)5.52 
Price/EarningsN/A 
Price/Sales (ttm)35.10 
Income Statements
Sales (ttm)$13.0M
EBITDA (ttm)-$30.1M
Income available to common (ttm)-$40.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-49.02%
Return on Equity (ttm)-51.87%
Financial Strength
Current Ratio (mrq)12.41 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$59.9M
Short Interest
As of 8-Aug-2001
Shares Short370.0K
Percent of Float3.2%
Shares Short
(Prior Month)
200.0K
Short Ratio9.25 
Daily Volume40.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.